Fluconazole-Loaded Ibuprofen In Situ Gel-Based Oral Spray for Oropharyngeal Candidiasis Treatment
- PMID: 38641711
- DOI: 10.1208/s12249-024-02804-y
Fluconazole-Loaded Ibuprofen In Situ Gel-Based Oral Spray for Oropharyngeal Candidiasis Treatment
Abstract
Oral candidiasis is a fungal infection affecting the oral mucous membrane, and this research specifically addresses on a localized treatment through fluconazole-loaded ibuprofen in situ gel-based oral spray. The low solubility of ibuprofen is advantageous for forming a gel when exposed to an aqueous phase. The 1% w/w fluconazole-loaded in situ gel oral sprays were developed utilizing various concentrations of ibuprofen in N-methyl pyrrolidone. The prepared solutions underwent evaluation for viscosity, surface tension, contact angle, water tolerance, gel formation, interface interaction, drug permeation, and antimicrobial studies. The higher amount of ibuprofen reduced the surface tension and retarded solvent exchange. The use of 50% ibuprofen as a gelling agent demonstrated prolonged drug permeation for up to 24 h. The incorporation of Cremophor EL in the formulations resulted in increased drug permeation and exhibited effective inhibition against Candida albicans, Candida krusei, Candida lusitaniae, and Candida tropicalis. While the Cremophor EL-loaded formulation did not exhibit enhanced antifungal effects on agar media, its ability to facilitate the permeation of fluconazole and ibuprofen suggested potential efficacy in countering Candida invasion in the oral mucosa. Moreover, these formulations demonstrated significant thermal inhibition of protein denaturation in egg albumin, indicating anti-inflammatory properties. Consequently, the fluconazole-loaded ibuprofen in situ gel-based oral spray presents itself as a promising dosage form for oropharyngeal candidiasis treatment.
Keywords: in situ gel; fluconazole; ibuprofen; oral spray; oropharyngeal candidiasis.
© 2024. The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists.
Similar articles
-
Clotrimazole-Loaded Borneol-Based In Situ Forming Gel as Oral Sprays for Oropharyngeal Candidiasis Therapy.Gels. 2023 May 15;9(5):412. doi: 10.3390/gels9050412. Gels. 2023. PMID: 37233003 Free PMC article.
-
VT-1161 protects mice against oropharyngeal candidiasis caused by fluconazole-susceptible and -resistant Candida albicans.J Antimicrob Chemother. 2018 Jan 1;73(1):151-155. doi: 10.1093/jac/dkx352. J Antimicrob Chemother. 2018. PMID: 29040636 Free PMC article.
-
Iranian HIV/AIDS patients with oropharyngeal candidiasis: identification, prevalence and antifungal susceptibility of Candida species.Lett Appl Microbiol. 2018 Oct;67(4):392-399. doi: 10.1111/lam.13052. Epub 2018 Aug 16. Lett Appl Microbiol. 2018. PMID: 30019443
-
Efficacy of Flavonoids in Combating Fluconazole Resistant Oral Candidiasis.Curr Pharm Des. 2022;28(21):1703-1713. doi: 10.2174/1381612828666220324140257. Curr Pharm Des. 2022. PMID: 35331090 Review.
-
Candida and candidaemia. Susceptibility and epidemiology.Dan Med J. 2013 Nov;60(11):B4698. Dan Med J. 2013. PMID: 24192246 Review.
Cited by
-
Moxifloxacin HCl -loaded Cellulose Acetate Butylate In Situ Forming Gel for Periodontitis Treatment.AAPS PharmSciTech. 2024 Oct 14;25(7):242. doi: 10.1208/s12249-024-02960-1. AAPS PharmSciTech. 2024. PMID: 39402367
-
Development and Evaluation of Cellulosic Esters Solvent Removal-Induced In Situ Matrices for Loading Antibiotic Drug for Periodontitis Treatment.Polymers (Basel). 2025 Jun 2;17(11):1551. doi: 10.3390/polym17111551. Polymers (Basel). 2025. PMID: 40508794 Free PMC article.
-
Cellulose Acetate Butyrate-Based In Situ Gel Comprising Doxycycline Hyclate and Metronidazole.Polymers (Basel). 2024 Dec 13;16(24):3477. doi: 10.3390/polym16243477. Polymers (Basel). 2024. PMID: 39771329 Free PMC article.
References
-
- Epstein JB, Polsky B. Oropharyngeal candidiasis: a review of its clinical spectrum and current therapies. Clin Ther. 1998;20:40–57. https://doi.org/10.1016/s0149-2918(98)80033-7 . - DOI - PubMed
-
- Sivannana S, Vishnuvardhana A, Elumalaib K, Srinivasanc S, Cherianb BV, Ramanujamd SK, et al. Azithromycin and co-trimoxazole-induced oral thrush: a case report from the perspective of pharmacy. Intell Pharm. 2023;1(4):280–2. https://doi.org/10.1016/j.ipha.2023.06.007 . - DOI
-
- Pisano M, Romano A, Di Palo MP, Baroni A, Serpico R, Contaldo M. Oral candidiasis in adult and pediatric patients with COVID-19. Biomedicines. 2023;11:846. https://doi.org/10.3390/biomedicines11030846 . - DOI - PubMed - PMC
-
- Karajacob AS, Azizan NB, Al-Maleki AR, Goh JP, Loke MF, Khor HM, et al. Candida species and oral mycobiota of patients clinically diagnosed with oral thrush. PLoS ONE. 2023;18(4):e0284043. https://doi.org/10.1371/journal.pone.0284043 . - DOI - PubMed - PMC
-
- Fang J, Huang B, Ding Z. Efficacy of antifungal drugs in the treatment of oral candidiasis: a Bayesian network meta-analysis. J Prosthet Dent. 2021;125(2):257–65. https://doi.org/10.1016/j.prosdent.2019.12.025 . - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources